RTP Mobile Logo
Myelodysplastic Syndromes Update, Issue 1, 2017
Released August 2017

Featuring interviews with Drs Mikkael A Sekeres and Steven D Gore. (Audio Content).

CE Disclosures and Faculty Information

    The clinical management of myelodysplastic syndromes (MDS) remains a challenge from both a diagnostic and a treatment standpoint, despite recent gains in the understanding of this heterogeneous disease. Determining which treatment approach is most appropriate requires careful consideration of patient characteristics, physician expertise and available health-system resources. To bridge the gap between research and patient care, this issue of Myelodysplastic Syndromes Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.


    • Recognize the key cancer-defining features of MDS, and counsel patients accordingly regarding their prognosis and treatment goals and options.
    • Appraise the role of molecular testing for MDS to facilitate diagnosis, prognostication and treatment decision-making.
    • Formulate a treatment algorithm for lower- and higher-risk MDS, considering patient- and disease-related factors, including cytogenetic abnormalities.
    • Consider the available efficacy and safety data with lenalidomide, with or without erythropoiesis-stimulating agents, in patients with low- to intermediate-risk MDS with and without del(5q), and identify patients with MDS appropriate for this treatment.
    • Evaluate the potential advantages of oral administration compared to the standard parenteral administration of hypomethylating agents. 
    • Ascertain the utility and consider the future role of novel agents such as luspatercept in the management of anemia in patients with MDS.
    • Recall promising investigational agents (eg, anti-PD-1/PD-L1 monoclonal antibodies, venetoclax, IDH1/2 inhibitors) and combination strategies, and counsel appropriately selected patients regarding clinical trial enrollment.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity contains an audio component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr SekeresAdvisory Committee: Celgene Corporation, Daiichi Sankyo Inc. Dr GoreAdvisory Committee and Consulting Agreement: Celgene Corporation; Contracted Research: Celgene Corporation, Genentech BioOncology.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Celgene Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: August 2017
    Expiration date: August 2018

Acknowledge and close

Listen to audio:
Myelodysplastic Syndromes Update, Issue 1, 2017
Released August 2017

Featuring interviews with Drs Mikkael A Sekeres and Steven D Gore. (Audio Content).

Read print: